Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives Consensus Rating of “Hold” from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) have been assigned a consensus recommendation of “Hold” from the fourteen analysts that are covering the firm, MarketBeat Ratings reports. Thirteen equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $20.25.

A number of equities analysts have recently issued reports on the company. Wedbush downgraded Fusion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $24.00 price target on the stock. in a research report on Tuesday, March 19th. Bloom Burton lowered Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Oppenheimer raised their price target on Fusion Pharmaceuticals from $13.00 to $15.00 and gave the stock an “outperform” rating in a report on Friday, January 5th. TD Cowen restated a “hold” rating on shares of Fusion Pharmaceuticals in a research note on Tuesday. Finally, B. Riley lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the company from $13.00 to $23.00 in a research report on Wednesday, March 20th.

Institutional Investors Weigh In On Fusion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC raised its stake in shares of Fusion Pharmaceuticals by 883.0% during the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock valued at $28,000 after buying an additional 2,649 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Fusion Pharmaceuticals by 2,064.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock worth $29,000 after buying an additional 2,869 shares during the last quarter. Millennium Management LLC acquired a new stake in Fusion Pharmaceuticals during the second quarter worth about $29,000. Schonfeld Strategic Advisors LLC purchased a new position in Fusion Pharmaceuticals during the first quarter valued at approximately $49,000. Finally, Renaissance Technologies LLC acquired a new position in Fusion Pharmaceuticals in the third quarter valued at approximately $51,000. 72.85% of the stock is owned by hedge funds and other institutional investors.

Fusion Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ FUSN opened at $21.26 on Monday. The stock has a market capitalization of $1.80 billion, a P/E ratio of -14.46 and a beta of -0.72. The company has a debt-to-equity ratio of 0.16, a current ratio of 15.01 and a quick ratio of 15.01. The business has a fifty day moving average price of $16.06 and a 200 day moving average price of $9.84. Fusion Pharmaceuticals has a 1-year low of $2.31 and a 1-year high of $21.55.

Fusion Pharmaceuticals (NASDAQ:FUSN) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. Equities research analysts expect that Fusion Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.